Scientific publisher Nature Publishing Group (NPG), UK, and BioCentury Publications, Inc., a source of biopharma business intelligence, have announced the second annual SciBX Summit on Innovation in Drug Discovery & Development. The Summit will be held October 29-30 in Boston, MA, at the Colonnade Hotel Boston.
The Summit will bring together key stakeholders from academia, biotech, pharma and the investment community with the goal of creating roadmaps for solving key translational issues in important emerging areas of drug discovery and development. This year's summit will consist of four tracks - Non-coding RNAs as tools and targets; New models in neurological diseases; CAR-based cellular therapies; and Epigenetics' second wind.
This year's line-up of panelists includes James Audia (Constellation), Bruce Booth (Atlas Venture), Art Krieg (RaNa) and Stuart Schreiber (Broad Institute).
The Summit is the result of a months-long process during which the SciBX editorial team convenes working groups of four to six key opinion leaders for each track. Following the Summit, the SciBX team will create a document outlining the conclusions of the Summit participants, with an emphasis on solving key problems in each of the four fields.
New for this year's Summit is the establishment of an Advisory Council that creates a link between the SciBX editorial team and companies at the forefront of innovative drug discovery. The 2013 Advisory Council includes Amgen Inc., AstraZeneca plc, Biogen Idec Inc., Merck & Co. Inc., GlaxoSmithKline plc., Novartis AG, and Sanofi.
